BEIJING, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Haiwainet, the website of the overseas edition of the People's Daily, today reported that the 2026 "Reviving Craft - Chinese Intangible Cultural Heritage and Contemporary Design" exhibition ("Reviving Craft"), organised by Sun Media Group, is being held at Somerset House in London from 16 to 27 September 2026. On 16 September 2026, Somerset House in London welcomed a waft of tea fragrance carried from the deep mountains of Yunnan. As an official special project of ...

BEIJING, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Julong Holding Limited ("Julong" or the "Company") (Nasdaq: JLHL), a growth-oriented provider of intelligent integrated solutions, today announced that, on September 28, 2026, it entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain investors for a private placement (the "Private Placement") of the Company's securities. This press release does not constitute an offer to sell or the solicitation of an offer to buy any secur ...

All measurable sequencing metrics show profound improvement over Platinum Pro BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single- molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum Pro instrument. Using a developmental sequencing kit that detects 18 amino ac ...

核心观点 - HUTCHMED宣布阿斯利康已向美国FDA提交ORPATHYS（savolitinib）联合TAGRISSO（osimertinib）的新药申请，用于治疗局部晚期或转移性非小细胞肺癌患者，这些患者肿瘤存在MET过表达或扩增，且在接受EGFR TKI治疗后出现疾病进展 [1] - 该新药申请基于全球SAFFRON III期试验，SAFFRON显示ORPATHYS联合TAGRISSO在PFS和OS方面均优于双药铂类化疗，安全性特征与各药物已知特征一致，无新的安全性问题 [2] - 该申请寻求批准一种生物标志物导向的全口服治疗选择，用于MET过表达或扩增患者在接受EGFR-TKI治疗后进展的情形 [8] - SAFFRON是首个在该治疗场景中证明PFS和OS具有统计学显著且临床意义改善的全球III期试验 [8] - SAFFRON建立在SACHI III期和SAVANNAH II期试验证据基础之上 [8] 疾病背景与未满足需求 - 肺癌是全球癌症死亡的首要原因，占癌症死亡的近四分之一（23%）[5] - 肺癌 broadly 分为NSCLC和小细胞肺癌，其中80-85%的患者诊断为NSCLC [5] - 约75%的NSCLC患者诊断为晚期疾病 [5] - 在美国和欧洲，约10-15%的NSCLC患者具有EGFRm NSCLC，而在亚洲该比例为30-40% [5] - 第三代EGFR TKI显著改善了EGFRm NSCLC患者的预后，但MET过表达或扩增是第三代EGFR-TKI治疗最常见的耐药机制之一 [3] - MET驱动的进展与不良预后相关，该治疗场景仍存在显著未满足的有效且耐受性良好的治疗需求 [3] - MET是一种酪氨酸激酶受体，在正常细胞发育中发挥重要作用，MET过表达或扩增可导致肿瘤生长和癌细胞转移进展 [6] - 估计34%的肿瘤在第三代EGFR TKI进展后会出现高水平MET过表达或扩增 [6] SAFFRON III期试验详情 - SAFFRON是一项随机、开放标签、多中心、全球III期试验，研究ORPATHYS（300 mg每日两次）联合TAGRISSO（80 mg每日一次）对比双药铂类化疗的疗效 [7] - 试验纳入338例EGFRm、局部晚期或转移性NSCLC伴MET过表达或扩增、在接受第一或第二线TAGRISSO治疗后疾病进展的患者 [7] - 试验在29个国家的230个中心入组患者，包括北美、欧洲、南美和亚洲 [7] - 主要终点为PFS，关键次要终点包括OS [7] - 患者使用SAVANNAH II期试验确定的高MET水平截断值进行前瞻性筛选 [9] - 在SAVANNAH中，MET过表达或扩增水平通过两种检测方法确定：免疫组化（IHC）检测癌细胞表面特定蛋白或标志物，荧光原位杂交（FISH）检测癌细胞特定DNA序列 [9] - SAFFRON结果将在2026年欧洲肿瘤内科学会（ESMO）大会的主席研讨会上展示 [2] ORPATHYS（savolitinib）概况 - ORPATHYS是一种口服、强效、高选择性的MET TKI，已在晚期实体瘤中展示临床活性 [10] - 该药物阻断因突变（如外显子14跳跃改变或其他点突变）、基因扩增或蛋白过表达导致的MET受体酪氨酸激酶通路的非典型激活 [10] - ORPATHYS在中国获批用于治疗MET外显子14跳跃改变的局部晚期或转移性NSCLC成人患者，是首个在中国获批的选择性MET抑制剂 [11] - ORPATHYS还在中国获得附条件批准，用于治疗MET扩增、至少接受过两种先前系统治疗后失败的局部晚期或转移性胃癌或胃食管交界处腺癌成人患者 [11] - ORPATHYS联合TAGRISSO在中国获批用于基于SACHI III期试验的EGFR突变阳性非鳞状NSCLC伴MET扩增、在EGFR TKI治疗后疾病进展的患者 [11] - 该联合方案还在瑞士获得临时授权，用于治疗局部晚期或转移性EGFRm NSCLC伴高水平MET过表达或扩增、既往接受TAGRISSO治疗后进展的患者，基于全球SAVANNAH II期试验结果 [11] - 全球随机SAFFRON III期试验在同一治疗场景中比较该联合方案与双药铂类化疗，于2026年8月报告阳性高水平结果，证明PFS和OS具有统计学显著且临床意义的改善 [11] - ORPATHYS由阿斯利康和HUTCHMED联合开发，由阿斯利康商业化 [4] TAGRISSO（osimertinib）概况 - TAGRISSO是一种第三代、不可逆EGFR-TKI，在NSCLC中具有 proven 临床活性，包括治疗中枢神经系统转移 [12] - TAGRISSO作为单药疗法在超过120个国家获批，包括美国、欧盟、中国和日本 [13] - 获批适应症包括：局部晚期或转移性EGFRm NSCLC的一线治疗、局部晚期或转移性EGFR T790M突变阳性NSCLC、早期EGFRm NSCLC的辅助治疗以及铂类放化疗后局部晚期不可切除NSCLC [13] - TAGRISSO还在超过80个国家获批与化疗联合用于局部晚期或转移性EGFRm NSCLC的一线治疗，包括美国、欧盟、中国和日本 [13] HUTCHMED公司概况 - HUTCHMED是一家创新型、商业化阶段的生物制药公司 [14] - 公司致力于靶向疗法和免疫疗法的发现、全球开发和商业化，用于治疗癌症和免疫性疾病 [14] - 自成立以来，公司专注于将内部发现的候选药物带给全球患者，前四款药物已在中国上市，其中首款药物还在全球包括美国、欧洲和日本获批 [14] 高管评论 - HUTCHMED代理首席执行官兼首席财务官Johnny Cheng表示，此次提交是继基于SACHI III期试验在中国获批后，将ORPATHYS联合TAGRISSO带给美国患者的重要一步 [4] - 全球SAFFRON III期试验的成功反映了HUTCHMED与阿斯利康在解决EGFR突变肺癌中MET驱动进展方面的长期合作 [4] - 公司承诺支持监管审查，使这一生物标志物导向、无化疗的口服联合方案可供符合条件的患者使用 [4]

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Energy Income Fund (TSX – ENI.UN) (the “Fund”) is pleased to announce that unitholders will have the opportunity to redeem up to 253,384 units (the “Units”) of the Fund. The annual redemption date has been set for November 27, 2026. Units will be redeemed for an amount per Unit equal to net asset value less redemption costs equal to 5% of net asset value per Unit plus applicable taxes (as contemplated in the Fund’s declaration of trust which is available on the Fu ...

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Citadel Income Fund (TSX – CTF.UN) (the “Fund”) is pleased to announce that unitholders will have the opportunity to redeem up to 262,689 units (the “Units”) of the Fund. The annual redemption date has been set for November 27, 2026. Units will be redeemed for an amount per Unit equal to net asset value less redemption costs equal to 5% of net asset value per Unit plus applicable taxes (as contemplated in the Fund’s declaration of trust which is available on the F ...

GRAND FALLS-WINDSOR, Newfoundland and Labrador, Sept. 28, 2026 (GLOBE NEWSWIRE) -- First Atlantic Nickel & Cobalt Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P210) ("First Atlantic" or the "Company") is pleased to announce that it has closed a no-warrant, non-brokered private placement (the "Offering") for aggregate gross proceeds of $3,767,700.25. Following this closing, the Company has raised aggregate gross proceeds of approximately $9.925 million from financings completed in September 2026. The Offering cons ...

I joined the Board and the Audit Committee as an independent director in January 2026, when Dr. Michael Price retired after many years of service. Prior to this I spent over 30 years working for CIBC Capital Markets and Macquarie Group in all aspects of mining finance including equity research, equity capital markets, mergers and acquisitions, debt finance and investing in growth-stage mining companies. I was initially attracted to Entrée for its carried interest in a portion of the world-class Oyu Tolgoi c ...

文章核心观点 - Galaxy Gaming旗下MONOPOLY Table Games Progressive在2026年Global Gaming Awards Americas上荣获年度产品创新奖 [1] - 该游戏通过与Hasbro的独家授权协议开发，将全球知名品牌转化为联动累进式桌面游戏体验，安装已覆盖北美和EMEA地区 [2] - 该奖项在G2E 2026展会期间颁发，公司同时推出MONOPOLY Building Riches、Spotlight Spin Progressive和Galaxy Link等新产品 [3][5] 产品与创新 - MONOPOLY Table Games Progressive将授权品牌与累进式头奖结合，为赌场带来全新体验 [3] - 该游戏自推出以来迅速成为行业最受关注的新产品之一，安装覆盖北美和EMEA地区 [2] - 公司在G2E 2026上推出MONOPOLY品牌新作MONOPOLY Building Riches，以及Spotlight Spin Progressive和连接两款新游戏的Galaxy Link技术 [5] - 展会于2026年9月28日至10月1日在Venetian Expo举行，公司展位号为4452 [5] 奖项与行业认可 - Global Gaming Awards Americas已进入第二个十年，由Gaming America和Gambling Insider制作，被视为游戏行业最负盛名的荣誉之一 [3] - 获奖者由C级行业高管评审团选出，投票过程独立监督以确保透明和公平 [3] - Hasbro业务发展总监Claire Hunter Gregson表示，MONOPOLY在赌场游戏中占据独特地位，其认知度和持久吸引力少有第三方品牌能匹敌 [4] - 该奖项反映了品牌实力以及Galaxy Gaming将MONOPOLY搬上赌场 floor 的创新 [4] 公司概况 - Galaxy Gaming总部位于内华达州拉斯维加斯，为全球实体和在线赌场开发并分销创新游戏、奖励系统和技术解决方案 [7] - Galaxy Gaming Digital是全球领先的专有桌面游戏在线游戏行业授权商 [7] - 公司在全球拥有超过140个许可证，包括美国28个州和全球30多个国家的许可证 [7] - 公司总裁兼CEO Matt Reback表示，该奖项对整个团队意义重大，尤其在G2E周期间获得认可更具意义 [3]

TORTOLA, British Virgin Islands, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Orca Energy Group Inc. (“Orca” or the “Company”) (TSX-V: ORC.A, ORC.B) today announced that its Board of Directors has declared a cash distribution (the “Special Distribution”) of $1.50 (Cdn) per Class A Common Voting Share (the “Class A Shares”) of the Company and $1.50 (Cdn) per Class B Subordinate Voting Share (the “Class B Shares”, and together with the Class A Shares, the “Common Shares”) of the Company. The Special Distribution will b ...